Benefit of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients

Cancer

Volumn 106, Issue 11, 2006, Pages 2337-2344

  Bria, Emilio ^a   Nistico, Cecilia ^a   Cuppone, Federica ^a   Carlini, Paolo ^a   Ciccarese, Mariangela ^a   Milella, Michele ^a   Natoli, Guido ^a   Terzoli, Edmondo ^a   Cognetti, Francesco ^a   Giannarelli, Diana ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adjuvant; Breast cancer; Chemotherapy paclitaxel; Docetaxel; Metaanalysis

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; TAXANE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; LYMPH NODE METASTASIS; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM STAGING; PACLITAXEL; SURVIVAL RATE; TAXOIDS;

EID: 33646873043     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21886     Document Type: Article

References (29)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2002;52:23-47.
2. Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998;1:3439-3460.
3. Bria E, Giannarelli D, Felici A, et al. Taxanes with anthracyclines as first line chemotherapy for metastatic breast cancer: pooled analysis of 2805 patients. Cancer. 2005;103:672-679.
4. Ghersi D, Wilken N, Simes J, et al. Taxane containing regimens for metastatic breast cancer (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons; 2003.
5. Buzdar AU, Singletary SE, Valero V, et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002;8:1073-9.
6. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003:976-983.
7. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686-3696.
8. Fountzilas G, Skarlos D, Dafni U, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005;16:1762-1771.
9. Gianni L, Baselga J, Eiermann W, et al. European Cooperative Trial in Operable breast cancer (ECTO): improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). J Clin Oncol (Meeting Abstracts). 2005;23:513.
10. Jones SE, Savin MA, Asmar L, et al. Three year results of a prospective randomized trial of adjuvant chemotherapy for patients (pts) with stage I-III operable, invasive breast cancer comparing 4 courses of doxorubicin/ cyclophosphamide (AC) to 4 courses of docetaxel/cyclophosphamide (TC). Proc Am Soc Clin Oncol 2003;22:15. Abstract 59.
11. Roche H, Fumoleau P, Spielmann M, et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Proceedings of the San Antonio Breast Cancer Symposium. Breast Ca Res Treat. 2004;88(suppl 1): S16. Abstract 27.
12. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302-2313.
13. Goldstein L, O'Neill A, Sparano J, et al. E2197: phase III AT (doxorubucin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. J Clin Oncol (Meeting Abstracts). 2005;23:512.
14. National Cancer Institute. Levels of evidence for adult cancer treatment studies, health professional version (date last modified: June 6, 2003). Available at: http://www-cancer. gov Accessed on May 19, 2004.
15. Pignon JP, Hill C. Meta-analyses of randomized clinical trials in oncology. Lancet Oncol. 2001;2:475-482.
16. Douglas-Case L, Kimmick G, Paskett ED, et al. Interpreting measures of treatment effect in cancer clinical trials. Oncologist. 2002;7:181-187.
17. Parmar MKB, Machin D. Survival Analysis: A Practical Approach. Chichester, UK: John Wiley & Sons; 1995.
18. Di Leo A, Bleiberg H. Overall survival is not a realistic endpoint for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol. 2003;21:2045-2047.
19. Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival [Abstract 510]. Proc Am Clin Oncol. 2004;23.
20. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812-2823.
21. Fisher B, Bryant J, Wolmark E, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-2685.
22. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998;16:93-100.
23. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930-942.
24. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
25. Piedbois P, Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol. 2004;22:3839-3841.
26. Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst. 2004;96:1141-1151.
27. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
28. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
29. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med. 2005;353:1734-1736.